Invesco DB Oil Fund vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Invesco DB Oil Fund trades at $24.04 (market cap $255.13M), while Nuvation Bio Inc. Class A Common Stock trades at $5.04 (market cap $1.74B). The key difference: Nuvation Bio Inc. Class A Common Stock is far larger — about 6.8× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| DBO | NUVB | |
|---|---|---|
Market Cap | $255.13M | $1.74B |
Volume | 562,167 | 9,289,619 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $9.54 |
52-Week Low | $11.98 | $3.41 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →